Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Sawyers
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ORIC Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
ORIC is a privately held company focused on discovery and development of novel therapies against treatment-resistant cancers. Dr. Sawyers project under this grant (RP-4: Investigating and targeting the glucocorticoid receptor (GR) in enzalutamide- and abiraterone-) has a focus on glucocorticoid receptors for targeting resistant cancer. ORIC’s business interests overlap with the focus of this work.
SPORE in Prostate Cancer
Project Narrative We are applying recent advances in our understanding of the biology of prostate cancer to develop new treatments that are matched to the specific underlying causes of an individual's disease. Our program will allow us to better distinguish between slow-growing cancers and those that require more aggressive treatment, better predict which drugs will work for which patients, better assess if the treatments patients are receiving are working, and develop new therapies for men with advanced disease who are not or no longer benefitting from available treatments.
Filed on August 30, 2018.
Tell us what you know about Charles Sawyers's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Charles Sawyers”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Sawyers | Sloan Kettering Inst Can Research | Conflict of Interest | ORIC Pharmaceuticals | Value cannot be readily determined |
| Charles Sawyers | Sloan Kettering Inst Can Research | Conflict of Interest | ORIC Pharmaceuticals | $60,000 - $79,999 |
| Charles Sawyers | Sloan Kettering Inst Can Research | Conflict of Interest | ORIC Pharmaceuticals | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.